Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Abbott Labs/Home Access

This article was originally published in The Tan Sheet

Executive Summary

Abbott Labs/Home Access: Firms sign an exclusive agreement to collaborate on development and marketing of home diagnostic tests employing Home Access' telemedicine technology. Abbott will market tests to be developed by Home Access, which also will be responsible for gaining FDA clearance and for providing related test result counseling services. Financial terms are not being disclosed. Hoffman Estates, Ill.-based Home Access says it is conducting research in the areas of genetics, cancer drugs, reproductive health and nutrition to determine which diagnostic tests have the most use and potential for the home telemedicine market. The firm is the only company marketing FDA-approved at-home diagnostic tests with counseling services -- the Home Access and Home Access Express HIV test systems. The firm notes that the tests under development likely will function along the same lines as the Home Access HIV test systems, which allow people to perform the test at home and anonymously obtain the results by phone...





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts